Targeted BRAF inhibition impacts survival in melanoma patients with high levels of Wnt/β-catenin signaling

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Chien, Andy J ^a,b   Haydu, Lauren E ^c,d   Biechele, Travis L ^a   Kulikauskas, Rima M ^a   Rizos, Helen ^c,d,e   Kefford, Richard F ^c,d,e,f   Scolyer, Richard A ^c,d,g   Moon, Randall T ^h   Long, Georgina V ^c,d,e,f  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b GROUP HEALTH RESEARCH INSTITUTE   (United States)

^c MELANOMA INSTITUTE AUSTRALIA   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e WESTMEAD HOSPITAL   (Australia)

^f WESTMEAD HOSPITAL   (Australia)

^g ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^h HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BETA CATENIN; WNT PROTEIN; WNT3A PROTEIN; BRAF PROTEIN, HUMAN; CTNNB1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE; WNT3A PROTEIN, HUMAN;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; GENETIC TRANSCRIPTION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MELANOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; WNT SIGNALING PATHWAY; YOUNG ADULT; ANTAGONISTS AND INHIBITORS; ENZYMOLOGY; GENE EXPRESSION REGULATION; MELANOCYTE; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; RETROSPECTIVE STUDY; SKIN NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR CELL LINE;

ADULT; AGED; BETA CATENIN; CELL LINE, TUMOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOCYTES; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME; WNT SIGNALING PATHWAY; WNT3A PROTEIN; YOUNG ADULT;

EID: 84899622207     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0094748     Document Type: Article

References (40)

1. Lens MB, Dawes M (2004) Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol 150: 179-185. (Pubitemid 38352453)
2. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, et al. (2002) BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62: 6997-7000. (Pubitemid 35424092)
3. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949-954. (Pubitemid 34716871)
4. Gorden A, Osman I, Gai W, He D, Huang W, et al. (2003) Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res 63: 3955-3957. (Pubitemid 36917911)
5. Libra M, Malaponte G, Navolanic PM, Gangemi P, Bevelacqua V, et al. (2005) Analysis of BRAF mutation in primary and metastatic melanoma. Cell Cycle 4: 1382-1384. (Pubitemid 41437127)
6. Loewe R, Kittler H, Fischer G, Fae I, Wolff K, et al. (2004) BRAF kinase gene V599E mutation in growing melanocytic lesions. J Invest Dermatol 123: 733-736. (Pubitemid 39281614)
7. Zalaudek I, Guelly C, Pellacani G, Hofmann-Wellenhof R, Trajanoski S, et al. (2011) The dermoscopical and histopathological patterns of nevi correlate with the frequency of BRAF mutations. J Invest Dermatol 131: 542-545.
8. Menzies AM, Haydu LE, Visintin L, Carlino MS, Howle JR, et al. (2012) Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res 18: 3242-3249.
9. Poynter JN, Elder JT, Fullen DR, Nair RP, Soengas MS, et al. (2006) BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res 16: 267-273. (Pubitemid 44090170)
10. Yazdi AS, Palmedo G, Flaig MJ, Puchta U, Reckwerth A, et al. (2003) Mutations of the BRAF gene in benign and malignant melanocytic lesions. J Invest Dermatol 121: 1160-1162. (Pubitemid 37430987)
11. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, et al. (2011) Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. New England Journal of Medicine 364: 9.
12. Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, et al. (2012) Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379: 1893-1901.
13. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, et al. (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380: 358-365.
14. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, et al. (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366: 707-714.
15. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, et al. (2010) COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468: 968-972.
16. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, et al. (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468: 973-977.
17. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N (2010) RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464: 427-430.
18. Shi H, Moriceau G, Kong X, Koya RC, Nazarian R, et al. (2012) Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. Cancer Discov 2: 414-424.
19. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, et al. (2010) Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18: 683-695.
20. Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, et al. (2011) Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 29: 3085-3096.
21. Chien AJ, Conrad WH, Moon RT (2009) A Wnt survival guide: from flies to human disease. J Invest Dermatol 129: 1614-1627.
22. Bachmann IM, Straume O, Puntervoll HE, Kalvenes MB, Akslen LA (2005) Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma. Clin Cancer Res 11: 8606-8614. (Pubitemid 43005907)
23. Chien AJ, Moore EC, Lonsdorf AS, Kulikauskas RM, Rothberg BG, et al. (2009) Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model. Proc Natl Acad Sci U S A 106: 1193-1198.
24. Gould Rothberg BE, Berger AJ, Molinaro AM, Subtil A, Krauthammer MO, et al. (2009) Melanoma prognostic model using tissue microarrays and genetic algorithms. J Clin Oncol 27: 5772-5780.
25. Kageshita T, Hamby CV, Ishihara T, Matsumoto K, Saida T, et al. (2001) Loss of beta-catenin expression associated with disease progression in malignant melanoma. Br J Dermatol 145: 210-216. (Pubitemid 32955344)
26. Maelandsmo GM, Holm R, Nesland JM, Fodstad O, Florenes VA (2003) Reduced beta-catenin expression in the cytoplasm of advanced-stage superficial spreading malignant melanoma. Clin Cancer Res 9: 3383-3388. (Pubitemid 37082733)
27. Biechele TL, Kulikauskas RM, Toroni RA, Lucero OM, Swift RD, et al. (2012) Wnt/beta-catenin signaling and AXIN1 regulate apoptosis triggered by inhibition of the mutant kinase BRAFV600E in human melanoma. Sci Signal 5: ra3.
28. Tsai J, Lee JT, Wang W, Zhang J, Cho H, et al. (2008) Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A 105: 3041-3046. (Pubitemid 351723664)
29. Conrad WH, Swift RD, Biechele TL, Kulikauskas RM, Moon RT, et al. (2012) Regulating the response to targeted MEK inhibition in melanoma: Enhancing apoptosis in NRAS-and BRAF-mutant melanoma cells with Wnt/beta-catenin activation. Cell Cycle 11: 3724-3730.
30. Scolyer RA, Murali R, McCarthy SW, Thompson JF (2010) Histologically ambiguous (''borderline'') primary cutaneous melanocytic tumors: approaches to patient management including the roles of molecular testing and sentinel lymph node biopsy. Arch Pathol Lab Med 134: 1770-1777.
31. Lucero OM, Dawson DW, Moon RT, Chien AJ (2010) A re-evaluation of the ''oncogenic'' nature of Wnt/beta-catenin signaling in melanoma and other cancers. Curr Oncol Rep 12: 314-318.
32. Damsky WE, Curley DP, Santhanakrishnan M, Rosenbaum LE, Platt JT, et al. (2011) beta-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell 20: 741-754.
33. Gallagher SJ, Rambow F, Kumasaka M, Champeval D, Bellacosa A, et al. (2012) Beta-catenin inhibits melanocyte migration but induces melanoma metastasis. Oncogene.
34. Yaguchi T, Goto Y, Kido K, Mochimaru H, Sakurai T, et al. (2012) Immune Suppression and Resistance Mediated by Constitutive Activation of Wnt/beta-Catenin Signaling in Human Melanoma Cells. J Immunol 189: 2110-2117.
35. Casiano CA, Ochs RL, Tan EM (1998) Distinct cleavage products of nuclear proteins in apoptosis and necrosis revealed by autoantibody probes. Cell Death Differ 5: 183-190. (Pubitemid 28356555)
36. Trefzer U, Minor D, Ribas A, Lebbe C, Siegfried A, et al. (2010) BREAK-2: a phase IIA trial of the selective BRAF kinase inhibitor GSK2118436 in patients with BRAF mutation-positive (V600E/K) metastatic melanoma. Pigment Cell & Melanoma Research 24: 1020.
37. Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, et al. (2012) Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 13: 1087-1095.
38. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. (2000) New Guidelines to Evaluate the Response to Treatment in Solid Tumors. Journal of the National Cancer Institute 92: 205-216. (Pubitemid 30099779)
39. Eisenhauer EA, Therasse P, Boggaerts J, Schwartz LH, Sargent D, et al. (2009) New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247.
40. Biechele TL, Moon RT (2008) Assaying beta-catenin/TCF transcription with beta-catenin/TCF transcription-based reporter constructs. Methods Mol Biol 468: 99-110.